Denali Therapeutics (DNLI) FY2020 results: revenue $336 million, up 1158.2% on the year
Denali Therapeutics Inc. (DNLI) reported revenue of $336 million for fiscal 2020, the year ended 31 December 2020, up 1158.2% on the year before. Net income was $71 million, and diluted earnings per share $0.63. The figures are the company's own, from the 10-K it filed with the SEC on 26 February 2021.
Revenue
$336 million
+1,158.2% on the year
FY2016FY2020
Operating margin
18.7%
-799.1% a year earlier
FY2016FY2020
Net income
$71 million
FY2016FY2020
Diluted EPS
$0.63
FY2016FY2020
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Revenue
336
26.7
129
+1,158.2%
Research and development
213
193
143
+9.9%
Operating income
62.7
-213
-46.4
Operating margin
18.7%
-799.1%
-35.9%
Income tax
0.8
-0.4
0.0
Net income
71.1
-198
-36.2
Net margin
21.2%
-740.7%
-28.1%
Diluted EPS
$0.63
-$2.07
-$0.39
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Operating cash flow
416
-152
50.1
Capital expenditure
3.1
17.9
3.4
-82.7%
Free cash flow
413
-169
46.7
Free cash flow margin
123.1%
-635.3%
36.2%
Cash from investing
-623
148
-287
Cash from financing
635
6.2
97.0
+10,154.4%
Depreciation and amortisation
8.5
8.0
7.4
+6.8%
Share-based compensation
50.4
38.4
18.8
+31.2%
Diluted shares, weighted
113m
96m
93m
+17.9%
Shares outstanding at period end
121m
96m
95m
+25.3%
Balance sheet
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Shareholders' equity
1,151
395
547
+191.4%
Debt
0.0
0.0
0.0
Operating lease liabilities
64.2
68.9
n/a
-6.8%
Other liabilities
390
89.5
115
+335.4%
Total liabilities and equity
1,604
553
662
+190.0%
Fixed assets
40.8
46.7
25.2
-12.6%
Investments
995
376
535
+164.8%
Cash and equivalents
507
79.4
77.1
+538.3%
Receivables
8.6
n/a
n/a
Other assets
52.4
51.3
24.6
+2.3%
Total assets
1,604
553
662
+190.0%
10-K for the year ended 31 December 2020, filed 26 February 2021: the filing.